載入...
Fibroblast growth factor 23: are we ready to use it in clinical practice?
Patients with chronic kidney disease (CKD) have a greatly enhanced risk of cardiovascular morbidity and mortality. Over the past decade it has come clear that a disturbed calcium-phosphate metabolism, with Fibroblast Growth Factor-23 as a key hormone, is partly accountable for this enhanced risk. Nu...
Na minha lista:
| 發表在: | J Nephrol |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Springer International Publishing
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7220896/ https://ncbi.nlm.nih.gov/pubmed/32130720 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40620-020-00715-2 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|